Can Existing Drugs Treat CMT?
HNF, in partnership with Rarebase, is leading the charge in the first-ever research initiative to tackle multiple types of CMT in one project using its tech-enabled drug discovery platform called "Function."
Presented by Rarebase
HNF, in partnership with Rarebase, is leading a first-of-its-kind research initiative to tackle multiple types of CMT in a single project. Using Rarebase’s technology-enabled drug discovery platform called “Function,” the initiative will screen a compound library of thousands of FDA-approved and novel drugs, targeting ten subtypes of CMT (Charcot-Marie-Tooth disease, a hereditary nerve disorder).
In this session, Rarebase Founder and COO Omid dives deeper into this platform and what it could mean for treating CMT.
To learn more about CMT research, visit our GRIN Registry page and explore how you can get involved.